Gruber-Rouh T, Langenbach M, Naguib NNN, Nour-Eldin NEM, Vogl TJ, Zangos S, Beeres M. Trans-arterial chemoperfusion for the treatment of liver metastases of breast cancer and colorectal cancer: Clinical results in palliative care patients. World J Clin Oncol 2017; 8(4): 343-350 [PMID: 28848701 DOI: 10.5306/wjco.v8.i4.343]
Corresponding Author of This Article
Tatjana Gruber-Rouh, MD, Institute for Diagnostic and Interventional Radiology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. tatjana.gruber-rouh@kgu.de
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Aug 10, 2017; 8(4): 343-350 Published online Aug 10, 2017. doi: 10.5306/wjco.v8.i4.343
Trans-arterial chemoperfusion for the treatment of liver metastases of breast cancer and colorectal cancer: Clinical results in palliative care patients
Tatjana Gruber-Rouh, Marcel Langenbach, Nagy N N Naguib, Nour-Eldin M Nour-Eldin, Thomas J Vogl, Stephan Zangos, Martin Beeres
Tatjana Gruber-Rouh, Marcel Langenbach, Nagy N N Naguib, Nour-Eldin M Nour-Eldin, Thomas J Vogl, Stephan Zangos, Martin Beeres, Institute for Diagnostic and Interventional Radiology, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany
Author contributions: Gruber-Rouh T and Beeres M designed and performed the research, statistical analysis and wrote the paper; Zangos S designed the research and supervised the report; Langenbach M designed the research and contributed to the analysis; Naguib NNN, Nour-Eldin NEM and Vogl TJ provided clinical advice; Vogl TJ and Zangos S supervised the report.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Goethe University Hospital, Frankfurt, Germany.
Conflict-of-interest statement: The authors have no financial relationships to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Tatjana Gruber-Rouh, MD, Institute for Diagnostic and Interventional Radiology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. tatjana.gruber-rouh@kgu.de
Telephone: +49-69-63018720 Fax: +49-69-63017258
Received: October 19, 2016 Peer-review started: October 23, 2016 First decision: January 14, 2017 Revised: April 27, 2017 Accepted: May 3, 2017 Article in press: May 5, 2017 Published online: August 10, 2017
Abstract
AIM
To evaluate the clinical value and efficiency of trans-arterial chemoperfusion (TACP) in patients with liver metastases from breast cancer (BC) and colorectal cancer (CRC).
METHODS
We treated 36 patients with liver metastases of BC (n = 19, 19 females) and CRC (n = 17; 8 females, 9 males) with repeated TACP. The treatment interval was 4 wk. TACP was performed with gemcitabine (1000 mg/m2) and mitomycin (10 mg/m2), administered within 1 h after positioning the catheter tip in the hepatic artery. Before treatment, the size, location, tumour volume, vascularization and number of liver tumours were evaluated using magnetic resonance imaging (MRI). Tumour response was evaluated according to the Response Evaluation Criteria in Solid Tumors guidelines.
RESULTS
TACP using gemcitabine and mitomycin for metastases from CRC and BC was performed without any serious side effects. The follow-up MRI showed a therapeutic response in 84.2% of the BC patients - stable disease 47.4% and partial response 36.8%. A progression was seen in 15.8%. CRC patients showed a therapeutic response in 52.9% of cases. A progression of the disease was documented in 47.1% of the patients with CRC. These data show that TACP in patients with liver metastases of BC leads to a significantly better therapeutic response compared with CRC patients (P = 0.042). The median survival time was 13.2 mo for the BC patients, which is significantly longer than for CRC patients at 9.3 mo (P = 0.001).
CONCLUSION
TACP for liver metastases of BC appears to be a safe and effective palliative treatment with improved outcomes in comparison to patients with CRC.
Core tip: Trans-arterial chemoperfusion could be an alternative treatment option for advanced stage palliative patients suffering from liver-dominant metastatic disease.
